Yale School of Medicine, Department of Therapeutic Radiology, 35 Park St., New Haven, CT 06519, USA.
The Ohio State University, Division of Medical Oncology, 320 West 10th Avenue, Columbus, OH 43210, USA.
Oral Oncol. 2019 Aug;95:29-34. doi: 10.1016/j.oraloncology.2019.05.013. Epub 2019 Jun 6.
Oral Mucositis (OM) continues to be an oncologic challenge in the context of antineoplastic therapy for head and neck cancer (HNC) treatment. It is a dose-limiting toxicity of chemotherapy and radiation treatment and negatively impacts quality of life and cancer treatment efficacy. Significant effort in the field of OM has been made to help alleviate its symptoms and its subsequent clinical and economic impact. Despite these advances, the treatment of oral mucositis remains difficult and focuses on palliative measures. There are, however, many promising new biological targets currently undergoing investigation to ameliorate or help prevent the toxicity of OM in HNC. Some of these targets undergoing investigation in phase 2 and 3 clinical trials are further highlighted along with the pathobiology of OM, clinical course, prevention, and management measures.
口腔黏膜炎（OM）仍然是头颈部癌症（HNC）治疗中抗肿瘤治疗的一个挑战。它是化疗和放疗的剂量限制毒性，会对生活质量和癌症治疗效果产生负面影响。在 OM 领域已经做出了很大的努力来帮助减轻其症状及其随后的临床和经济影响。尽管取得了这些进展，口腔黏膜炎的治疗仍然很困难，主要集中在姑息治疗措施上。然而，目前有许多有前途的新的生物靶点正在被研究，以减轻或帮助预防 HNC 中 OM 的毒性。其中一些正在进行 2 期和 3 期临床试验的靶点，以及 OM 的发病机制、临床病程、预防和治疗措施，都得到了进一步的强调。
